- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
February 2021 turned out to be slow month for Indian Pharma: AIOCD-AWACS data

New Delhi: COVID crisis showed a negative impact on the Indian pharmaceutical market (IPM) in February as the recent data from market research firm All India Organization of Chemist and Druggist (AIOCD-AWACS) claimed a drastic fall with growth rate for the monthAs per AIOCD AWACS data, the trend of growth in January 2021 with growth of 4.5% has decreased to 1.1% in February 2021. The...
New Delhi: COVID crisis showed a negative impact on the Indian pharmaceutical market (IPM) in February as the recent data from market research firm All India Organization of Chemist and Druggist (AIOCD-AWACS) claimed a drastic fall with growth rate for the month
As per AIOCD AWACS data, the trend of growth in January 2021 with growth of 4.5% has decreased to 1.1% in February 2021. The running quarter growth of Dec-Jan-Feb 21 was highlighted to be 4.7%
The data further revealed that while majority of the therapy areas have moved to the recovery path, a few therapy areas that contribute a significant chunk to the IPM are yet to show positive traction.
Post-Unlockdown since June'20m the struggle for Anti-infectives continued with a negative growth rate of 2.7% in January 2021 fell further to negative growth of 11.3% in Feb 21. Meanwhile, its associated therapy like Gastroenterology exhibited growth of 9.9 % in Feb 2021 vs 14.3% in Jan'21, Vitamins showed a growth of 8.6% in Feb Vs 12.2 % Jan 21 and Pain & Analgesics are at 2.3% in Feb'21 vs 5.0 % in Jan 21.
A detailed analysis showed that February'21 witnessed stability in cardiac drugs but with lower growth of 7.3% as compared to 8.8% in January'21. Similarly, Anti-Diabetics registered a growth of 4.3% compared to 5.3% in January'21 while respiratory medicines growth slumped to -20.3% compared to -14.1 % in January '21.
Considering the market performance, Glycomet GP manufactured by USV Private Limited topped the list of highest-selling brands this month, followed by Abbott's Mixtard, and Sanofi's Lantus.
Medical Dialogues Bureau consists of a team of passionate medical/scientific writers, led by doctors and healthcare researchers. Our team efforts to bring you updated and timely news about the important happenings of the medical and healthcare sector. Our editorial team can be reached at editorial@medicaldialogues.in.